HOME >> MEDICINE >> NEWS
Study shows infliximab can maintain long-term remissions in Crohns disease

Periodic treatment with the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's disease, a multi-center research team reports today at the Digestive Disease Week meeting in Atlanta.

The ACCENT-I clinical trial is the first large-scale trial of infliximab (also known as REMICADE) used as maintenance therapy instead of as a treatment for acute attacks. The researchers found that after 30 weeks of therapy, patients receiving infusions of infliximab every eight weeks were twice as likely to be in remission as those who were not receiving the drug.

"This is the first therapy that truly allows us to manage this disease over time, rather than just treating flare ups," said lead investigator Stephen Hanauer, M.D., professor of medicine at the University of Chicago and director of the study. "Ongoing treatment with infliximab decreased disease activity, prevented sudden attacks, and enabled patients to reduce or, in many cases, completely eliminate steroids."

Infliximab was well tolerated throughout the 30 weeks of this trial without any unanticipated side effects.

Crohn's disease, a chronic inflammatory bowel disorder, affects approximately 500,000 Americans, typically beginning in late childhood or early adulthood. The disease causes inflammation of the gastrointestinal tract. It can result in diarrhea, fever, abdominal pain and weight loss. In up to 30 percent of patients, Crohn's disease causes fistulas -- openings that burrow through the bowel wall into nearby organs or through the surface of the skin.

The researchers enrolled 573 patients with moderate to severe Crohn's disease at 55 centers in North America, Europe, and Israel. All patients received an initial dose of infliximab. The 335 patie
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
20-May-2001


Page: 1 2 3

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... ... November 15, 2018 , ... ... and products, now accepts Flexible Spending Account (FSA) and Health Savings Account (HSA) ... reduce the burden of healthcare spending for customers and improve the overall shopping ...
(Date:11/15/2018)... Texas (PRWEB) , ... November 15, 2018 , ... ... the latest version of its paperless, web-based eForms solution for hospitals . ... and enables users to launch eForms directly from any of these systems, have ...
(Date:11/14/2018)... ... November 14, 2018 , ... Racial and ... and in regions experiencing shortages. The Association of American Medical Colleges has ... , Researchers from the American Board of Family Medicine (ABFM) aggregated racial and ...
(Date:11/14/2018)... ... November 14, 2018 , ... Contrary to ... recycled consumer product. Lead batteries hold the honor at a whopping 99.3 percent, ... Day 2018 on November 15, the lead battery industry is proudly sharing the ...
(Date:11/13/2018)... ... November 14, 2018 , ... REMS: ... Webinar**, Nov. 28, 2018 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/remsrre ... It’s now a powerful enforcement tool. A constantly evolving enforcement tool. , In ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 15, 2018 , ... The ... More Than 100 Million Users , The Bluntness Furthers Maven’s Commitment to Innovative ... with Maven, a coalition of over 300 exclusive publishers and brands, powered by ...
(Date:11/15/2018)... ... ... Joint Implant Surgeons (JIS) , a world leader in outpatient joint ... group practice centers in the nation to be selected to participate in the Zimmer ... and hip replacement—will be transformed by the Zimmer Biomet mymobility app, which uses Apple ...
(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... ... world data, today announced that the company has been awarded a $225,000 Phase ... of the National Institutes of Health (NIH). , The pursuit of useful, well-structured ...
Breaking Medicine Technology:
Cached News: